Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
Kris Levin-Snow, area vice president within AT&T‘s national security group, will now oversee the company’s defense industrial base portfolio in addition…
Rocket Lab has signed a definitive agreement to acquire California-based Motiv Space Systems, adding space robotics and precision spacecraft mechanism…
Sonny Bhagowalia, assistant commissioner for information and technology and chief information officer at U.S. Customs and Border Protection, has received…
NextPoint Group expands intelligence-focused capabilities with UScontracting acquisition by adding expertise in cybersecurity, signals intelligence and data analysis for national…
